Hi,
Okay, it's rather late in my country ATM, I am tired and sleepy and do not quite understand the article called "Are the MK-4 and MK-7 Forms of Vitamin K2 Equivalent?" mentioned by adreno*, but last week I decided to order some vit K2, mk7 (from natto) to be exact, from Now Foods**, and one of the things I stumbled on was the thing I'll paste below.
To me it was one of the more recent studies that showed that mk7 is just as good as mk4 - better even because less is needed (mcgs instead of mgs). Hopefully it will be of some interest to one/some of you.
But hey, maybe I missed an important clue in that 2009 article. In that case: forgive me, I was/am about to go to bed.
Quote:
MENAQ7®: 3 Year Human Study with Vitamin K2 Demonstrates That MenaQ7® Significantly Improves Bone Strength, And Prevents Cardiovascular Aging.
22 May, 2012 15:54 CET
22nd May 2012 Oslo, Norway. NattoPharma today announces the presentation of the recently completed milestone 3-year clinical trial investigating beneficial effects of nutritional doses of natural vitamin K2 (MenaQ7®) on bone and vascular health.
At Geneva’s Vitafoods 2012, Dr. Cees Vermeer, Principal Investigator at VitaK laboratory at Maastricht University, has presented data showing significant benefits for improved bone strength and prevention of cardiovascular aging with daily supplementation of MenaQ7.
In the study, 244 healthy postmenopausal women received for 3 years daily 180 µg K2 from MenaQ7 or a placebo. The clinical measurements included bone mineral density, bone strength, vascular characteristics by ultrasound and pulse-wave velocity (PWV), the latter evaluating age-related stiffening of blood vessels.
MenaQ7 supplementation provided a statistically significant protection of the most vulnerable bone structures i.e. vertebrae and the hip. One of the important findings from the study was that clinically relevant improvement at the site of the femoral neck became evident no sooner than after 2 and 3 years of MenaQ7 supplementation. This finding explains for the first time why shorter studies typically failed to show benefits of vitamin K on bone health and cardiovascular health.
“This study is a breakthrough for MenaQ7 and for the Vitamin K2 market”, stated Executive Chairman in NattoPharma Frode Bohan “never in history such clinical effects have been scientifically documented with Vitamin K2 at nutritional dosage”.
The MenaQ7 trial showed substantial benefits in preventing age-related stiffening of arteries resulting in increase of the PWV in the placebo group, but not in the MenaQ7-group. Most remarkably, MenaQ7 not only prevented stiffening, it also resulted in an unprecedented statistically significant improvement of vascular elasticity both measured with ultrasound techniques and PWV. Previously the positive effects on bone and vascular health have been demonstrated with a pharmacological dose of synthetic forms of vitamin K, of up to 45 milligrams per day. The MenaQ7 study shows for the first time in history of vitamin K evaluation the positive health effects with a “nutritional” dose of vitamin K. Remarkably, the low-dose MenaQ7 effects were even more pronounced than those in trials using a high dose of one of the synthetic forms of vitamin K.
# # #
About MenaQ7
MenaQ7 provides natural vitamin K2 as a fermentation extract whereby vitamin K2 is manufactured using bacillus subtilis natto. This process has the capacity of producing the highly pure and bio-available form of vitamin K2, menaquinone-7 (MK-7). MenaQ7 is the best documented, commercially available natural vitamin K2 with guaranteed actives and stability, clinical substantiation and international patents granted and pending.***
/quote.
*
http://wholehealthsource.blogspot.se/2009/03/are-mk-4-and-mk-7-forms-of-vitamin-k2.html?m=1
**
http://www.nowfoods.com/Supplements/Products-by-Category/Joint-Structural-Support/081877.htm
***
http://www.cisionwire.com/nattophar...aq7--significantly-improves-bone-str,c9262978